Introduction
Nasopharyngeal carcinoma (NPC) is the commonest head and neck cancer in Southern China; it is the fifth commonest cancer in men in Hong Kong. Radiotherapy is the primary treatment modality of NPC. The technique of intensity-modulated radiotherapy (IMRT) further enhances the efficacy of radiotherapy for NPC and studies have shown that IMRT alone offers excellent locoregional control in early-stage NPC [1] [2] [3] . When comparing with conventional two-dimensional radiotherapy (2 DRT), there is less radiation to the adjacent structures like parotid glands and temporomandibular joints when IMRT is employed for treatment of early NPC [4] . Studies have shown that IMRT improves the quality of life of NPC patients after radiotherapy when compared to conventional 2 DRT, especially in regard to preservation of salivary function [1, 5] . Radiation can damage the inner ear structures and neural pathways leading to hearing loss [6, 7] . Long-term follow-up studies have shown that NPC patients suffered from significant sensorineural hearing loss after radiotherapy treatment [8, 9] . The unique advantage of IMRT in offering adequate radiation dosage to the tumor while reducing the radiation dosage to the surrounding normal tissue may reduce the longterm sensorineural hearing loss in NPC patients treated with radiotherapy. In this study, we compare the longterm hearing results and otological complications in two groups of patients: one group treated with conventional 2 DRT and the other group treated with IMRT. In order to avoid the confounding factor of ototoxicity from chemotherapy, no patients in the cohort received chemotherapy. From January 2001 to March 2005, patients with UICC 2002  stage II NPC (T1N1, T2N0, T2N1 disease) were treated with radiotherapy alone with either 2 DRT or IMRT. As IMRT was a novel treatment at that time, 2 DRT was the standard of care. The choice of radiotherapy was based either on the trial setting or the patient's preference or physician's decision. The pretreatment evaluation included a complete history and physical examination, nasopharyngoscopy, chest X-ray, complete blood count, liver and renal biochemistry. Patients were staged with contrast computed tomography scans to determine the eligibility to enter the study. None of the patients received neoadjuvant, concurrent or adjuvant chemotherapy, as our institution treatment protocol did not employ chemotherapy for stage II disease.
Materials and Methods

Patients
Two-Dimensional Radiotherapy
2 DRT was performed in 2 sequential phases. Phase I started with 2 large lateral opposing faciocervical fields covering the nasopharynx and upper cervical lymph nodes and any parapharyngeal extension. 40 Gy was given in 2 Gy/fraction, 5 fractions per week in 4 weeks. After 40 Gy, phase II treatment continued with 1 anterior facial and 2 lateral opposing fields to the nasopharynx to avoid the spinal cord to another 28 Gy in the same fractionation. The total dose to the nasopharynx was 68 Gy in 34 fractions. As the temporal bones were irradiated in both lateral fields during both phase I and phase II 2 DRT, the dose to the temporal bones is considered the same as the dose to the nasopharynx, that is, about 68 Gy. The lower neck was treated with a separate anterior cervical field with a midline shield to protect the spinal cord. The dose to the neck was 66 Gy in 33 fractions.
Intensity-Modulated Radiotherapy
The nasopharynx and upper neck were treated with IMRT. IMRT was performed with Corvus system (MIMiC from NO-MOS, Sewickley, USA). Treatment targets and organs at risk were localized on planning computed tomography scans with the patient in immobilization cast. The gross tumor volume included the tumor in the nasopharynx and any tumor extension outside the nasopharynx identified clinically or radiologically. The clinical target volume covered the gross tumor volume with margins to include any potential microscopic disease extension. The clinical target volume typically extended from the skull base to level II, III nodal regions on both sides. The planning target volume was the clinical target volume with an additional 3-mm margin to account for a potential set-up error in treatment. The dose to the planning target volume to the nasopharynx was 68-70 Gy in 34 fractions, 5 daily fractions per week. The lower neck was treated in a matching anterior cervical field, with a midline shield, to 66 Gy in 33 fractions. The inner, middle and external ears on both sides were localized as organs at risk in IMRT planning and the doses to these structures were limited to 50 Gy.
Audiological and Otological Assessments
All patients underwent otoscopic assessment by an otolaryngologist and pure-tone audiogram by an audiologist before the start of radiotherapy. Patients with otitis media with effusion were offered myringotomy and grommet insertion. A repeat pure-tone audiogram was obtained if the patient underwent grommet insertion, and the postoperative audiogram was used for baseline assessment. The pure-tone audiogram included air conduction at the frequencies 256 Hz, 512 Hz, 1 kHz, 4 kHz and 8 kHz and bone conduction (BC) at the frequencies 512 Hz, 1 kHz, 2 kHz and 4 kHz. Masking thresholds were obtained whenever it was appropriate. Patients had an audiogram performed 5 years after radiotherapy. As air conduction thresholds could be affected by middle ear pathologies, to measure the effect of radiation damage to the inner ear, the BC thresholds were used for statistical calculations. Similar to a previous study by Ho, we calculated the pure-tone average (PTAv), the average of thresholds at 512 Hz, 1 kHz, and 2 kHz to reflect the threshold in speech range [8] . The BC threshold at 4 kHz was chosen to represent high-frequency threshold. Since the maximal output of the bone conductor of the audiometer is 65 dB, it would not be possible to accurately measure the true threshold if the BC threshold was worse than 65 dB. For ears with a BC threshold worse than 65 dB and no clinical or tympanometrical evidence of conductive hearing loss, the BC threshold is assumed to be equivalent to the air conduction threshold.
Patients had otoscopic or microscopic examination of the ears by otolaryngologists in the year 2010, 5-9 years after completion of radiotherapy. Otitis media with effusion, eardrum perforation, grommet and osteoradionecrosis (ORN) of the external auditory canal were noted. The presence of exposed bone with bony sequestrum in the external auditory canal was used as the diagnostic hallmark of ORN of the external auditory canal [10] . Otitis media with effusion was confirmed with the presence of type B curve on tympanometry.
Statistical Calculations
Individual ears are used for statistical calculations. The serial change in hearing of individual ears after radiotherapy was determined by the paired t test. For comparison of the changes in hearing of patients who received 2 DRT versus IMRT, the change in the hearing threshold was calculated and the significance deter-mined by t test. The 2 test and Fisher exact test were used for comparison of the occurrence of ORN, the presence of grommets, otitis media with effusion and perforations between the two groups. A two-tailed p value of less then 0.05 was considered significant. All statistical tests were calculated with SPSS 18.0 (Chicago, Ill., USA).
Results
Eighty-two patients (63 male and 19 female), i.e. 164 ears were included in the study, with each ear considered as an independent case. The age of patients ranged from 27 to 75 years old, with a median age of 46 years. There are 40 patients in the conventional 2 DRT group and 42 patients in the IMRT group. There was no difference in the age, sex distribution and pretreatment audiological threshold between the two groups of patients. A summary of the demographic data is shown in table 1 . Eleven patients died within 5 years of completion of radiotherapy. Four patients developed local recurrence in the nasopharynx and were all salvaged with nasopharyngectomy via the maxillary swing; these 4 patients are excluded from the study. One patient developed recurrence in the right parotid region and received a second dose of radiotherapy. One patient developed disseminated disease and received cisplatin chemotherapy. Both patients were excluded from the study. Twelve patients were lost to follow-up.
Audiological Results
Complete audiological information 5 years after irradiation was available for 106 ears. Fifty-six and 50 ears received IMRT and conventional radiotherapy, respectively. There was no statistical difference in the age of the two groups of patients (p = 0.38, t test). Preirradiation hearing level and audiological information at the 5-year follow-up were analyzed. For the PTAv, the overall mean preirradiation BC level was 17.9 dB (SD = 9.2) and the mean level at the 5-year follow-up was 24.6 dB (SD = 16.6). Compared with the preirradiation hearing threshold, there was an average deterioration of hearing of 6.6 dB (95% CI 4.4-8.9) 5 years after radiotherapy, which was statistically significant (paired t test, p ! 0.001). At 4 kHz, the overall mean preirradiation BC level was 26.4 dB (SD = 17.1) and the mean BC level at the 5-year followup was 41.4 dB (SD = 26.0). The mean deterioration of hearing at 4 kHz was 15.0 dB (95% CI 2.0-21.1), which was again significant (paired t test, p ! 0.001). Table 2 shows the BC thresholds of the whole cohort before and after radiotherapy.
The average deteriorations in PTAv in the 2 DRT group and IMRT group are 7.0 and 6.2 dB, respectively, and this is not statistically significant (p = 0.74, t test). The average deteriorations in hearing at 4 kHz in the 2 DRT and IMRT group are 13.8 and 16.2 dB, respectively, and this is statistically not significant (p = 0.57, t test). Table 3 summarized the hearing results of the two groups of patients. The average difference in the change in hearing between the two groups of patients is less than 5 dB and clinically this small difference is not significant. 
Otological Complications
Ninety-four ears (47 patients), i.e. 52 ears in the IMRT group and 42 ears in the 2 DRT group, were available for otological assessment. In the IMRT group, 1 out of 52 ears (1.9%) had ORN while in the conventional radiotherapy group, 6 in 42 ears (14.3%) had ORN. The difference in the occurrence of ORN between the two groups was significant (Fisher's exact test, p = 0.042). Otitis media with effusion was present in 14 ears (26.9%) in the IMRT group and 3 ears (7.1%) in the conventional radiotherapy group. The difference between the two groups was significant (p = 0.016, Fisher's exact test). One ear in the IMRT group and 1 ear in the 2 DRT group had a grommet present during otological assessment. One ear in the IMRT group and 1 ear in the 2 DRT group had a chronic perforation of the tympanic membrane. Table 4 summarizes the otological findings.
In summary, we observed a statistically significant deterioration in the BC threshold in the speech frequency and in the high tone in the whole cohort 5 years after radiotherapy treatment for NPC. However, we are unable to demonstrate any difference in the deterioration of BC threshold between patients treated with IMRT or 2 DRT. Patients who received 2 DRT have a higher incidence of developing ORN of the external auditory canal compared with patients who received IMRT. In contrast, patients who received IMRT have a higher incidence of otitis media with effusion than patients who received 2 DRT.
Discussion
Radiation therapy has been known to damage the auditory apparatus and hearing. A previous study at our institute demonstrated the presence of long-term hearing loss after radiotherapy for NPC [8] , and the present study confirmed this finding. The deterioration in hearing could not be attributed to aging alone. Robinson and Sutton had calculated that the expected age-related threshold shift in 5 years should be in the range of 2.6-4.6 dB for 4 kHz and 1.3-1.4 dB for the PTAv. The present study showed that the average change in hearing thresholds 5 years after radiotherapy are 15.2 dB at 4 kHz and 7.3 dB for the PTAv. The present study also demonstrated that there is more significant damage to the high-frequency hearing than speech frequency after radiotherapy. Moreover, many studies on hearing deterioration after radiotherapy for NPC included patients at a more advanced stage and who had received chemotherapy. Chemotherapy, especially cisplatin, is cytotoxic. Chemotherapy will be a confounding variable in many of the studies. In the current cohort, none of the patients had received chemotherapy. There could be other confounding factors affecting hearing in the patients in the 5 years after radiotherapy like diabetes, noise exposure and genetic factors. We are unable to control these factors regarding their contribution to hearing loss and these confounding variables may contribute to the negative findings in the difference in hearing between the two groups.
IMRT offers the radiotherapist the advantage of sparing the adjacent organs high-dose radiation and should improve the quality of life of patients after radiotherapy. The improvement of quality of life after radiotherapy for NPC has been demonstrated in the aspect of preservation of salivary function [1, 5] . In order to achieve the preservation of salivary function, the contralateral parotid gland has been deliberately excluded from the high-dose zone during radiotherapy planning. On the other hand, the petrous temporal bone, cochlea and Eustachian tube were considered as at-risk organs and limited to a maximum of 50-Gy radiation. Therefore, the cochlea may well receive a radiation dose that will cause damage to hearing and this can explain the similar deterioration in hearing between the IMRT group and 2 DRT group. Chen et al. [11] demonstrated that a radiation dose over 48 Gy to the cochlea would significantly increase the risk of sensorineural hearing loss; though in his study, patients also received ototoxic chemotherapy. In another cohort of patients with head and neck cancer treated with IMRT, Zuur et al. [12] demonstrated that the dose to the cochlea, pretreatment hearing loss, green-eyed patients and older age were all risk factors for posttreatment hearing loss, though the authors did not present a maximum safe dose for the cochlea for hearing preservation. In our current cohort, the patients in the IMRT group received a dose of 50 Gy to the cochlea while the 2 DRT group received a dose of up to 68 Gy. As both groups of patients in the current study received more than 48 Gy of radiation to the cochlea, this might explain the fact that there is no difference in the hearing loss between both groups.
ORN of the external auditory canal and tympanic ring is a serious complication of radiotherapy. The condition affects the quality of life of the patients. ORN was due to endarteritis and subsequent avascular necrosis of the bone, first described by Ewing [13] . Ramsden et al. [14] divided temporal bone ORN into the localized form and the diffuse form. Both forms of temporal bone ORN include the tympanic ring, where blood supply is precarious, with the diffuse form involving parts of the temporal bone in addition to the tympanic ring. ORN is a difficult condition to manage. Patients present with recurrent otorrhea that requires frequent aural toileting and treatment of infection. ORN of the temporal bone can also lead to serious complications including facial nerve palsy and cerebrospinal fluid otorrhea. In severe cases, surgical intervention including radical debridement of the necrotic bone and flap reconstruction may be required [15] . Moreover, patients with ORN of the temporal bone frequently suffer from chronically discharging ears, making the use of conventional hearing aids difficult. A recent report described the use of a bone-anchored hearing aid to circumvent the problem of discharging ears in hearing rehabilitation of this group of patients [16] .
The present study showed that there is much less incidence of ORN of the temporal bone in patients who have received IMRT when compared to patients who have received conventional 2 DRT. In conventional 2 DRT, the radiation to the nasopharynx is delivered by a lateral opposing field. The lateral opposing fields include the tympanic ring and petrous temporal bone and both structures receive a high dose of radiation. In IMRT, the radiation is delivered by several beams from different angles to the nasopharynx. The tympanic ring, which is situated further away from the nasopharynx and clinical tumor volume, would thus receive a lesser dose of radiation than when using conventional 2 DRT. This may explain the observed reduction of ORN in patients who received IMRT. In a similar study, Hsin et al. [17] also demonstrated that patients treated with IMRT suffered from less otological complications but a similar incidence of sensorineural hearing loss.
We cannot find a plausible explanation for the increased incidence of otitis media with effusion in patients who received IMRT. The results from the study by Hsin et al. [17] showed a similar incidence of otitis media with effusion in patients receiving conventional 2 DRT or IMRT. Further research will be required to look into the effect of IMRT on the Eustachian tube functions of NPC patients.
In conclusion, there is a significant reduction in the incidence of ORN of the external auditory canal in patients who had received IMRT but there is no clinical and statistical difference in the long-term BC hearing thresholds in NPC patients who had received IMRT or 2 DRT. IMRT can reduce the long-term otological complications of NPC patients.
